source
- Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AMLCourtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.onclive · 2mo ago↗ source
- Tirabrutinib and CAR T-Cell Therapy Represent Potential Paradigm Shifts in R/R PCNSLAshley Sumrall, MD, FACP, FASCO, discusses emerging data for tirabrutinib and the evolving role of CAR T-cell therapy in primary central nervous system lymphoma.onclive · 2mo ago↗ source
- Valneva to cut up to 15% of jobs as reduced travel hits vaccine demandFrench vaccine maker Valneva is laying off 10% to 15% of its workforce and reducing revenue projections due to "an emerging adverse trend in travel vaccine uptake across key markets." The drugmaker